NCT06853678 2025-03-03
Second-line Immunotherapy for ES-SCLC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Recruiting
Tianjin Medical University Cancer Institute and Hospital
University of Texas Southwestern Medical Center
Georgetown University
Rigshospitalet, Denmark
Ohio State University Comprehensive Cancer Center